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Objective: Sulfur mustard is a well-known blistering chemical warfare agent that has
been investigated for its toxicological mechanisms and an efficacious antidote. Since
sulfur mustard injury involves dermal:epidermal separation, proteolytic enzymes were
suspected to be involved for this separation and eventual blister development. Therefore,
protease inhibitors could be of therapeutic utility against sulfur mustard injury. In this
study, the effects of Kunitz-domain 1 of human tissue factor pathway inhibitor-2 were
evaluated against the toxic effects of 2-chloroethyl ethyl sulfide, a surrogate agent of
sulfur mustard. Tissue factor pathway inhibitor-2 is a 32-kDa serine protease inhibitor
produced by a variety of cell types including human epidermal keratinocytes, fibrob-
lasts, and endothelial cells. It consists of 3 Kunitz-domains and the first Kunitz-domain
contains the putative P1 residue (arginine at position 24) responsible for protease in-
hibitory activity. Methods: Recombinant wild-type and R24Q mutant Kunitz-domain
1s were expressed in Escherichia coli and purified. The purified proteins were refolded,
and their effects were tested in an in vitro human epidermal keratinocyte cell wounding
assay. Results: Wild-type but not R24Q Kunitz-domain 1 inhibited the amidolytic ac-
tivity of trypsin and plasmin. Wild-type Kunitz-domain1 was stable for 4 weeks at 42˚C
and for more than 8 weeks at room temperature. Wild-type Kunitz-domain 1 signifi-
cantly improved wound healing of unexposed and 2-chloroethyl ethyl sulfide–exposed
cells without influencing cell proliferation. Although R24Q Kunitz-domain 1 lacked
trypsin and plasmin inhibitory activity, it promoted wound closure of untreated and
2-chloroethyl ethyl sulfide–treated cells but to a much lesser degree. Conclusion:
These data suggest that wild-type Kunitz-domain 1 of human tissue factor pathway
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inhibitor-2 can be developed as a medical countermeasure against sulfur mustard cuta-
neous injury.
Sulfur mustard (HD, bis-(2-dichloroethyl) sulfide) is a chemical warfare agent that
penetrates skin rapidly and causes erythema, edema, necrosis, and extensive blistering.
Presently, there is no pretreatment or effective antidote for HD injury. Proteases are re-
leased and/or induced because of HD exposure and are suggested to be responsible for the
formation of blisters.1−3 Therefore, protease inhibitors capable of inhibiting HD-induced
and/orreleasedproteasesmayofferprotectionagainstHDinjury.Compoundscreeningcon-
ducted by US Army Medical Research Institute of Chemical Defense revealed that topical
application of serine protease inhibitors, namely, N-tosyl-L-lysine chloromethyl ketone and
ethyl p-guinidinobenzoate hydrochloride, reduced HD toxicity in the mouse ear vesicant
model. On the basis of these studies, it was suggested that serine protease inhibitors could
be beneficial against HD toxicity in vivo.4 Recently, it was found that serine and matrix
metalloprotease (MMP) inhibitors, namely aprotinin and ilomastat, have offered protection
against HD-induced lung injury in rats.5,6
Tissue factor pathway inhibitor-2 (TFPI-2) is a member of the Kunitz-type family
of serine protease inhibitors with strong homology to the classical tissue factor path-
way inhibitor (TFPI-1).7 It is a 32-kDa broad-spectrum serine protease inhibitor and in-
hibits a variety of proteases including trypsin, plasmin, chymotrypsin, cathepsin G, plasma
kallikrein, and factor VIIa–tissue factor complex with nanomolar affinity.7,8 TFPI-2 has
also been reported to inhibit some MMPs either directly or indirectly. While the study
conducted by Du et al failed to observe inhibition of activated MMP-1 by recombinant
TFPI-2 and its binding to MMP-1, MMP-2, and MMP-9,9 some studies observed di-
rect inhibition of MMP-1, MMP-2, MMP-9, and MMP-13.10,11 We reported the ability
of TFPI-2 to negatively regulate MMPs including MMP-1, MMP-2, and MMP-9 by in-
hibiting their activation from proenzymes.12 A wide variety of cells, including human
epidermal keratinocytes, dermal microvessels, and dermal fibroblasts, synthesize and se-
crete TFPI-2.13−15 Secreted TFPI-2 tightly binds to connective tissue matrix involving
glycosaminoglycans.16,17 Structurally, TFPI-2 consists of 3 Kunitz-domains (KDs) and the
first KD (KD1) contains putative P1 residue (arginine at position 24) that is responsible
for the inhibition of trypsin, plasmin, and factor VIIa-tissue factor complex.18 Mutating
the P1 residue from arginine (R) to glutamine (Q) (R24Q) caused significant loss of the
inhibitor’s activity toward trypsin, plasmin, and factor VIIa-tissue factor activity.18 Human
recombinant TFPI-2 inhibited extracellular matrix destruction and invasion by cancer cells
and tumor angiogenesis.19 In light of these properties, such as broad specificity and extra-
cellular matrix localization, TFPI-2 has a possible role in extracellular matrix degradation
andremodelingassociatedwithphysiologicalandpathologicalsituationsincludingcellmi-
gration,cellinvasion,woundhealing,angiogenesis,atherosclerosis,andtumorinvasionand
metastasis.
Inthisstudy,wetestedtheprotectiveeffectsofhumanrecombinantwild-typeKD1(wt-
KD1) and R24Q mutant KD1 (R24Q-KD1) against the toxic effects of 2-chloroethyl ethyl
sulfide(CEES),asurrogateagentofHD,inaninvitrohumanepidermalkeratinocyte(HEK)
cell wounding assay. Our results suggest that wt-KD1 and, to a significantly lesser extent,
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R24Q-KD1 promoted wound closure of unexposed and CEES-exposed HEK, suggesting
beneficial effects for wt-KD1 against HD injury.
MATERIALS AND METHODS
Materials
Expressionvector,pET15b,andEcolistrainBL21(DE3)werepurchasedfromNovagenInc
(Madison, WI). Quick Ligation Kit and restriction endonucleases, Nde1 and BamH1, were
purchased from New England Biolabs (Beverly, MA). DNA purification kits were obtained
from Qiagen Inc (Valencia, CA). Thrombin CleanCleave Kit, chromogenic substrate H-D-
Val-Leu-Lys-p-nitroanilide(S2251),humanplasmin,bovinetrypsin,andallotherchemicals
were obtained from Sigma Chemical Co (St Louis, MO). QuikChange XL site-directed
mutagenesiskitwaspurchasedfromStratagene(LaJolla,CA).AmiconUltra-15centrifugal
filter devices were purchased from Millipore Corp (Bedford, MA). HEK was obtained from
ATCC(Manassas,VA).Definedkeratinocyte-SFM,growthsupplements,andtrypsin-EDTA
werepurchasedfromLifeTechnologiesInc(Gaithersburg,MD).PfuDNApolymerase,calf
intestinal alkaline phosphatase, and CellTiter 96 AQueous One Solution Cell Proliferation
Assay kit were purchased from Promega Corp (Madison, WI). Nickel–Sepharose high-
performance resin for His-Trap column was obtained from Amersham Biosciences Corp
(Piscataway,NJ).CoomassieBlue(Biosafe),acrylamideandbisacrylamide,silverstaining,
and protein determination kits were obtained from Bio-Rad Laboratories (Richmond, CA).
Recombinant human TFPI-2 expressed from mammalian cells and anti-human TFPI-2 IgG
were generously provided by Dr Walter Kisiel (University of New Mexico Health Sciences
Center, Albuquerque, NM).
Expression and puriﬁcation of wt-KD1 and R24Q-KD1
DNA encoding the wt-KD1 of human TFPI-2 was cloned into pET15b expression plasmid
according to standard procedures. With this expression system, KD1 was made as a fusion
protein containing6Xhistidine tag at its amino terminus, which could be removed by incu-
bation with thrombin. To make a point mutation on KD1 (R24Q), site-directed mutagenesis
was performed using QuickChange XL site-directed mutagenesis kit according to the man-
ufacturer’s instruction. The recombinant construct was examined for in-frame orientation
and integrity by nucleic acid sequencing. The KD1 fusion proteins were expressed in E coli
growni nL Bbroth containing 100 µg/mL of ampicillin and induced at 37˚C with 1 mM
isopropyl-thiogalactopyranoside (IPTG) at mid-log phase (A600 = 0.6–0.7) for 2 hours.
InducedcellswereharvestedandlysedbyFrenchPressingin30mMTris-HCl(pH8.0)
containing 1 mM EDTA. Inclusion bodies were collected by subjecting the lysate to cen-
trifugation at 17000 × g for 30 minutes at 4˚C and washed once with the same buffer. The
inclusion bodies were solubilized overnight in PBS containing 6 M guanidine HCl and cen-
trifuged at 12000 × g for 30 minutes at 4˚C. Supernatant was collected and filtered through
0.2 micron pore size filters, and then the filtrate was loaded onto a His-Trap column. The
column was washed with PBS containing6Mguanidine HCl (equilibration buffer), fol-
lowed by washing with equilibration buffer containing 25 mM imidazole. wt-KD1 fusion
protein was eluted from the column in equilibration buffer containing 500 mM imidazole.
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His-trapcolumnelutedwt-KD1wasnotactiveagainsttrypsinandplasmin.Torecover
the enzyme inhibitory activity for His-trap column eluted wt-KD1 fusion protein, it was
reduced and refolded as described.20,21 Refolded wt-KD1 fusion protein was then filtered
through 0.2 micron pore size filters and subjected to fast protein liquid chromatography
(FPLC),usingHiTrapQanionexchangecolumn.Proteinwaselutedfromthecolumnusing
a linear 0–1 M NaCl gradient. Column fractions were analyzed by SDS-PAGE followed
by Western blotting and/or silver staining to identify wt-KD1 fusion protein. Fractions
containing pure wt-KD1 fusion protein were pooled and digested with thrombin using
Thrombin CleanCleave Kit following the manufacturer’s protocol. Complete digestion of
wt-KD1 fusion protein by thrombin was confirmed by SDS-PAGE. Thrombin-cleaved wt-
KD1 was applied onto Amicon Ultra-15 centrifugal filter device for removing His6 peptide
and for concentration of the sample. Each batch of the pure wt-KD1 was characterized with
respect to protein concentration, purity, and inhibition kinetics as previously described.8
R24Q mutant KD1 was also expressed and purified by His-trap column and FPLC
anion-exchange chromatography as described above for wt-KD1.
Trypsin and plasmin inhibition assays
The inhibitory activities of TFPI-2, wt-KD1, and R24Q-KD1 against trypsin and plasmin
weredeterminedaspreviouslydescribed.8Trypsin(0.1nM)andplasmin(0.2mU)wereeach
incubated with various concentrations of TFPI-2, wt-KD1, and R24Q-KD1 for 15 minutes
atroomtemperature.Chromogenicsubstrate(S-2251,0.08mM)wasthenadded,andresid-
ual amidolytic activity was measured at 405 nm using Spectramaxplus microplate reader
(Molecular Devices). Full-length TFPI-2 expressed in mammalian cells was included as a
positive control.
In vitro wound healing assay
The in vitro wound healing assay using HEK was performed as described.22 HEK cells
were seeded in 12-well tissue culture plates (2 × 105cells/ per well) and grown in defined
keratinocyte-serum-free medium containing growth supplements. Twenty-four hours after
seeding, a linear wound was made by scraping HEK monolayer with a pipette tip, followed
by extensive washing with the growth medium to remove cellular debris. The wt-KD1 (1,
10, 20, 50, or 100 nM) or R24Q-KD1 (1, 10, 20, 50, or 100 nM) were added immediately
after washing, and wound closure was monitored for 48 hours. Cell images were obtained
using an inverted microscope (Olympus 1 × 71) attached with a camera (Olympus DP12).
In some experiments, HEK monolayers were exposed to 0 to 500 µM CEES for
24hours.Thenalinearwoundwasmadeandwoundclosurewasmonitoredandrecordedas
described above. To investigate the effect of wt- and R24Q-KD1s, 125 µM CEES-exposed
and wounded HEK were incubated with increasing concentrations of these 2 proteins (10,
20, 50, or 100 nM), and monitored for wound closure as described above.
Cell proliferation assay
HEK proliferation rate was measured by using a CellTiter 96 AQueous one-solution cell
proliferation assay. HEK cells were plated in 96-well plate at a density of 3000 cells per
well. Next day, the cells were treated with wt-KD1 (1, 10, 20, 50, or 100 nM) or R24Q-KD1
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(1, 10, 20, 50, or 100 nM) for 48 hours. Then, 20 µLo fCellTiter 96 AQueous one-solution
was added to each well. After 3 hours of incubation, absorbance at 490 nm was measured
using Spectramaxplus microplate reader. All assays were done in triplicates, and average
and the standard deviation were shown.
In some experiments, HEK were first exposed with 125 µM CEES for 24 hours and
then treated with wt-KD1 (1, 10, 20, 50, or 100 nM), or R24Q-KD1 (1, 10, 20, 50, or
100 nM) for 48 hours and cell proliferation was determined as described above.
Western blotting
Proteins were boiled for 5 minutes, separated by SDS-PAGE using 15% polyacrylamide
gels,andelctroblottedontonitrocellulosemembrane.23 Afterelctroblotting,themembranes
were blocked with 3% nonfat dry milk in 10 mM Tris-HCl with 150 mM NaCl (pH 7.4) and
0.1% Tween-20 (TTBS) for 2 hours at room temperature. The membranes were then incu-
bated overnight at 4˚C with anti-TFPI-2 antibody (diluted 1:3000 in TTBS with 1% BSA).
Afterseveralwashes,themembraneswereincubatedfor1hourwithperoxidase-conjugated
secondary antibody (diluted 1:3000 in TTBS containing 1% BSA). After several washes in
TTBS, the immunoreactive proteins were identified by using an enhanced chemilumines-
cence reagent system according to the manufacturer’s instructions.
Other methods
SDS-PAGE was performed using 15% or 18% mini-slab gels.24 Proteins were identified
by staining with Coomassie blue. Protein concentration was determined by the dye binding
methodwithaBio-Radproteinassaykitaccordingtothemanufacturer’sinstructions.Silver
staining was performed using the Bio-Rad silver stain kit following the manufacturer’s
instructions.
RESULTS
Expression, puriﬁcation, and refolding of wt-KD1
Wt-KD1 protein was expressed in E coli growni nL Bcontaining 100 µg/mL of ampicillin.
Inductionat37˚Cwith1mMIPTGatmid-logphasefor2hoursshowedthehighestamount
ofwt-KD1expression(Figure1A,lane3).Theseconditionswereadoptedforthelarge-scale
expression of both wt- and R24Q-KD1s.
The expressed wt-KD1 went into inclusion bodies, suggesting that the protein was
insoluble and biologically inactive (Figure 1A, lane 3). Inclusion bodies were solubilized
with 6 M guanidine HCl and His-affinity chromatography was performed to purify the wt-
KD1. Refolding of His-affinity column purified wt-KD1 was accomplished by subjecting
the protein to reduction with 50 mM dithiothreitol and then dialysis in a buffer containing
2Murea,0.3MNaCl,2.5mMreducedglutathione,0.5mMoxidizedglutathione,and0.2M
arginine for 96 hours.20 SDS-PAGE of the refolded wt-KD1 suggests that it was relatively
a pure protein with a molecular size of 10.6 kDa (Figure 1A, lane 2). This analysis also
revealed that the purified wt-KD1 sample contained few minor contaminating proteins,
16CHOI ET AL
Figure 1. Prokaryotic expression and purification of wt-KD1: Panel A: SDS-
PAGEofHis-affinitycolumnpurifiedwt-KD1.Lanesare(1)molecularweight
markers;(2)columnpurifiedwt-KD1and(3)inclusionbodyextract.Thearrow
points to the location of wt-KD1. Panel B: SDS-PAGE of FPLC fractions.
FPLC fractions were processed by SDS-PAGE, using 15% polyacrylamide
gel, and proteins were identified by silver staining. Lanes are (1) molecular
size markers; (2) wt-KD1 purified with His-affinity column; and (3–10) FPLC
fractions from A6–A13. Fractions A8–A12 (lanes 5–9) contained the pure wt-
KD1 fusion protein. Panel C: SDS-PAGE of wt-KD1 without His-tag. Lanes
are (1) molecular size marker; (2) wt-KD1 with His-tag (solid arrow); and (3)
wt-KD1 without His-tag (dashed arrow). Panel D: Molecular composition of
refolded wt-KD1. Proteins were fractionated using 15% polyacrylamide gels
and identified by Western blotting using anti-TFPI-2 antibody. Lanes are (1)
wt-KD1 with His-tag and (2) wt-KD1 without His-tag. Wt-KD1 with His-tag
contains both monomers (dashed arrow) and multimers (solid arrows) where
as wt-KD1 without His-tag contains monomers only.
specifically with molecular size more than 55 kDa (Figure 1A, lane 2). An average of
3.5 mg of wt-KD1 was obtained from1Lo ft h eIPTG-induced LB broth.
To remove the high-molecular-weight contaminating proteins, wt-KD1 was then sub-
jected to FPLC using HiTrap Q HP column. Wt-KD1 binds to HiTrap Q HP resin and was
elutedfromthecolumnwithasaltconcentrationrangingfrom0.2Mto0.4M.FPLCcolumn
fractions were assessed for wt-KD1 by SDS-PAGE followed by silver staining (Figure 1B).
Column fractions 8–12 contained the pure wt-KD1, suggesting that high-molecular-weight
contaminants were removed by FPLC anion exchange chromatography (Figure 1B, lanes
5–9).
To remove the His-tag from the refolded wt-KD1, FPLC fractions containing wt-KD1
werepooled,concentrated,andincubatedwiththrombin.SDS-PAGEofthethrombindigest
reveals that the molecular size of wt-KD1 without the His-tag was 8.7 kDa (Figure 1C, lane
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3) as compared with 10.6 kDa for the wt-KD1 with His-tag (Figure 1C, lane 2). Complete
removal of His-tag from refolded wt-KD1 fusion protein was also confirmed by Western
blotting with anti 6 X histidine antibodies. The antibody reacted with refolded wt-KD1
before incubation with thrombin but not after incubation (data not shown). Collectively, the
data show that His-tag was completely removed from refolded wt-KD1.
It was shown that refolding of recombinant wt-KD1 fusion protein yields monomeric
andmultimericforms.25 Therefore,weanalyzedthemolecularcompositionofrecombinant
wt-KD1 by SDS-PAGE and Western blotting with anti-TFPI-2 antibodies (Figure 1D).
Wt-KD1 before the removal of His-tag contained both monomeric and multimeric forms
confirming the earlier observations (Figure 1D, lane 1). In contrast, His-tag–removed wt-
KD1 was homogenously monomeric (Figure 1D, lane 2). These results suggest that the
recombinant wt-KD1 used in the present study was monomeric form.
Expression, puriﬁcation, and refolding of R24Q-KD1
Methods described above for the expression, purification, and refolding of wt-KD1 were
usedforobtainingrecombinantR24QmutantKD1.SDS-PAGEconfirmedthatR24Q-KD1
wasapure protein with a molecular size similar to that of the wt-KD1 (data not shown).
Enzyme inhibition of wt-KD1 and R24Q-KD1
In these studies, the ability of wt-KD1 and R24Q mutant KD1 to inhibit the amidolytic
activities of bovine trypsin and human plasmin were compared (Figure 2). Full-length
TFPI-2expressedinmammaliancellswasincludedasapositivecontrol.Wt-KD1inhibited
theamidolyticactivitiesofbothtrypsinandplasmininadose-dependentmanner,suggesting
thatrefoldedwt-KD1wasbiologicallyactive(Figure2Aand2B,darkgraybars).Incontrast,
R24Q-KD1 lacked inhibitory activity toward both trypsin and plasmin, suggesting the
importance of arginine at position 24 for the inhibitor activity (Figure 2A and 2B, black
bars). These results confirm the earlier observations that showed lack of enzyme inhibitory
activityforR24Q-TFPI-2againsttrypsin,plasmin,andfactorVIIa-tissuefactorcomplex.18
Figure 2. Inhibitiononplasmin(A)andtrypsin(B)byTFPI-2(graybars),wt-KD1(darkgrey
bars), and R24Q-KD1 (black bars). Increasing concentrations of inhibitors were incubated
withplasminandtrypsinasdescribedunderthesection“MaterialsandMethods.”Theresidual
amidolytic activity was represented as OD405 /per minute. All values were the mean ± SD of
triplicate samples.
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The inhibitory activities of wt-KD1 toward plasmin and trypsin were compared with
those for the full-length mammalian TFPI-2. On a molar basis, wt-KD1 (Figure 2A and
2B, dark gray bars) was 40–50% less active than the full-length TFPI-2 (Figure 2A and 2B,
gray bars). This observation contradicts an earlier study that showed that the trypsin and
plasmin inhibitory activities for refolded wt-KD1 were stronger than those for full-length
TFPI-2.25 Reason(s) for the discrepancy between our data and the data reported earlier by
Chand et al25 may be due to the structural differences between the 2 proteins. Recombinant
wt-KD1 produced in the previous study contains 10 X histidine tag whereas the wt-KD1
produced in the current study was without His-tag. Consequently, the molecular size of wt-
KD1 in the earlier study was 12–14 kDa whereas it was 8.7 kDa for the wt-KD1 produced
in the current study.
Thermal stability of wt-KD1
In these studies, thermal stability of wt-KD1 was assessed and compared to that of TFPI-2
overan8-weekperiod(Figure3).Recombinantproteinswereincubatedatdifferentdegrees
of temperature, and their ability to inhibit plasmin and trypsin amidolytic activities were
analyzed. At 65˚C, the inhibitory activity of wt-KD1 toward plasmin was completely lost in
4days(Figure3A)whereastrypsininhibitoryactivitywaslostin1day(Figure3B).Wt-KD1
was thermally stable for 4 weeks at 42˚C and for more than 8 weeks at room temperature
(Figure 3A and 3B). Similar results were observed for TFPI-2 (Figure 3C and 3D). These
results suggest that the refolded wt-KD1 is stable for extended periods of incubation.
Figure 3. Thermal stability of wt-KD1. Wt-KD1 (panels A and B) and mammalian full-
length TFPI-2 (panels C and D) were incubated at different temperatures for varying periods
oftimeandtheirabilitytoinhibitamidolyticactivitiesofplasmin(panelsAandC)andtrypsin
(panels B and D) were determined. All values were the mean ± SD of triplicate samples.
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Figure 4. Effectofwt-KD1andR24Q-KD1onHEKwoundhealing.HEKcultureswerewounded
as described under the section “Materials and Methods” and incubated with either 0, 1, 10, 20,
50, and 100 nM of wt-KD1 (upper panels a–f, respectively) or 0, 1, 10, 20, 50, and 100 nM of
R24Q-KD1 (lower panels g–l, respectively). Scale bar, 120 µm. The experiment repeated 3 times
and similar results were observed.
Effect of wt- and R24Q-KD1s on the wound closure of HEK in vitro
We analyzed the effect of wt and R24Q-KD1s on the wound healing of HEK in an in vitro
wound healing assay where the cells were wounded, treated with increasing concentrations
(1–100 nM) of wt-KD1 or R24Q-KD1, and monitored for the wound closure by migrating
cells for 48 hours. As shown in Figure 4, wound closure was faster for HEK treated with
wt-KD1 but not with R24Q-KD1. At the end of 48 hours, wound closure was not observed
for untreated HEK whereas it was complete for HEK treated with 20 nM or higher concen-
trations of wt-KD1 (Figure 4, upper panels) and to a significantly lesser extent with similar
concentrations of R24Q-KD1 (Figure 4, lower panels).
Effect of wt and R24Q-KD1s on the wound closure of HEK exposed to CEES
We also analyzed the effect of wt- and R24Q-KD1s on the wound healing of HEK exposed
to CEES by the in vitro wound healing assay. First, the effect of increasing concentrations
of CEES on HEK wound closure was studied. As shown in Figure 5A, CEES inhibited
the wound closure of HEK in a dose-dependent manner. Wound gap was greater as the
concentration of CEES was increased from 125 to 250 µM and from 250 to 500 µM.
Next, the effect of wt- and R24Q-KD1s on wound closure of 125 µM CEES-exposed
HEK was investigated. In this experiment, confluent HEK cultures were first exposed with
125µMofCEESfor24hoursandthenwounded.Followingwounding,HEKwereincubated
withincreasingconcentrationsofwtandR24Q-KD1s(10–100nM)andwoundclosurewas
monitored for 48 hours. As shown in Figure 5B, both wt (panels b–e) and R24Q-KD1
(panels g–j) promoted wound closure of CEES-exposed HEK in a dose-dependent manner.
Nevertheless, the effect of wt-KD1 was much greater than that of R24Q-KD1 on a molar
basis.
Effect of wt-KD1 and R24Q-KD1 on proliferation of HEK
To address the mechanism of enhanced wound closure of unexposed and CEES-exposed
HEK by wt-KD1 and to a lesser extent by R24Q-KD1, their effects on HEK proliferation
wasi nvestigated. As shown in Figure 6, both wt-KD1 (Figure 6A and 6C) and R24Q-KD1
(Figure6Band6D)havenoinfluenceontheproliferationofunexposed(Figure6Aand6B)
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Figure 5. Effect of wt-KD1 and R24Q-KD1 on the wound closure of HEK exposed to
CEES. A: HEK cultures were exposed to 0 µM (panel a), 125 µM (panel b), 250 µM (panel
c), and 500 µM (panel d) of CEES for 24 hours, and wound closure was recorded after 48
hours. B: The CEES (125 µM) exposed HEK were wounded and then treated with 10, 20,
50,or100nMofwt-KD1(panelsb–e,respectively),or10,20,50,or100nMofR24Q-KD1
(panels g–j, respectively), and wound closure was recorded after 48 hours. CEES-exposed
HEK without any treatment represents as a control (panels a and f). Scale bar, 120 µm. The
experiment was repeated 3 times and similar observations were made.
Figure 6. Effect of wt-KD1 and R24Q-KD1 on HEK proliferation. The cell proliferation of
HEK were measured as described under the section “Materials and Methods” and incubated
with either 0, 1, 10, 20, 50, and 100 nM of wt-KD1 (panel A) and 0, 1, 10, 20, 50, and 100 nM
of R24Q-KD1 (panel B) for 24 hours and cell proliferation was measured with A490 after 48
hours. The CEES (125 µM) exposed HEK were treated with 0, 1, 10, 20, 50, or 100 nM of wt-
KD1 (panel C), or 0, 1, 10, 20, 50, or 100 nM of R24Q-KD1 (panel D), and cell proliferation
was measured with A490 after 48 hours. The cell number was calculated from absorbance at
490 nm. All values were the mean ± SD of triplicate samples.
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as well as 125 µM CEES-exposed HEK (Figure 6C and 6D) during a period of 48 hours.
Theseresultssuggestthatthewoundclosureeffectsofwt-andR24Q-KD1sareindependent
of HEK proliferation.
DISCUSSION
In the present study, recombinant wt-KD1 was produced and tested for its efficacy in
improvingwoundhealingofCEES-injuredHEKinaninvitrowoundhealingmodel.Inthis
model,alinearwoundwascreatedbyscrapingcellsandmonitoredforclosurebymigrating
cells from the edge of the wound. Substances that help closing this artificial wound faster
are considered to positively influence wound healing in vivo. Therefore, this assay may
be considered as a prescreening model to select for substances/drugs with potential to be
beneficial in the treatment of chemical and burn wounds in vivo. In this study, we used
CEES, a surrogate agent of HD, to create artificial wounds and show that recombinant
wt-KD1 enhances wound closure and that this protein may be beneficial against HD injury
in vivo.
It has been suggested that proteases are necessary for the progression of HD-induced
woundsandthatproteaseinhibitorsmayofferprotection.Itwasshownthatcertainsynthetic
serine protease inhibitors, namely TLCK, and compound 1579 suppressed HD-increased
interleukin-8 in HEK as well as reduced HD toxicity in a mouse ear vesicant model.1−6 On
thebasisofthesestudies,wepredictedthatnaturallyoccurring,stable,smallmolecularsize,
and broad-spectrum serine protease inhibitors could be beneficial in the treatment of HD
wounds. Wt-KD1 of human TFPI-2 is an ideal candidate that has all the above-mentioned
characteristics. It is (1) a 8.7-kDa protein, (2) produced in E coli in milligram quantities,
(3) easily refolded so that the recombinant protein is biologically active, (4) stable at room
temperature for nearly 8 weeks and for 4 weeks at 42˚C, (5) exhibits inhibitory activity
against trypsin, plasmin, and factor VIIa-tissue factor complex, and (6) its R24Q mutant
KD1 lacking enzyme inhibitory activity provides a suitable control to understand the role
of serine protease activity in HD toxicity. Therefore, we produced recombinant wt-KD1
and R24Q-KD1 and tested their beneficial activity against HD injury in the in vitro wound
healing assay.
Our results provide evidence that wt-KD1 significantly promotes wound closure of
unexposed and CEES-exposed HEK, suggesting that this protein is of therapeutic interest
againstHDinjury.Surprisingly,R24Q-KD1lackingtrypsin,plasmin,andfactorVIIa-tissue
factor inhibitory activity also demonstrated wound-healing-promoting activity, suggesting
that wound closure of unexposed and CEES-exposed HEK is regulated not only by serine
protease inhibitory activity but also by other activities/mechanisms. Apparently, some of
these activities are contained within R24Q-KD1 also. For example, Kamei et al18 found
that R24Q-KD1, while lacking trypsin and plasmin activities, acquired strong inhibitory
activity toward factor Xa. Therefore, R24Q-KD1 may have acquired the ability to influence
certain proteases, as yet unidentified, which may play a role in the wound closure of HEK.
In summary, our results provide evidence that wt-KD1 of TFPI-2 could be beneficial
againstHDinjury.Itsbiochemicalandphysicalcharacteristics,suchassmallmolecularsize,
broad specificity, and long-term stability at physiological temperatures and above makes it
an attractive candidate as a medical countermeasure against HD injury.
22CHOI ET AL
REFERENCES
1. Cowan FM, Yourick JJ, Hurst CG, et al. Sulfur mustard-increased proteolysis following in vitro and in vivo
exposures. Chem Biol Toxicol. 1993;9:269–277.
2. Cowan FM, Bongiovanni B, Broomfield CA, Yourick JJ, Smith WJ. Sulfur mustard increases elastase-like
activities in homogenates of hairless guinea pig skin. Toxicol Cut Ocul Toxicol. 1994;13:221–229.
3. Powers JC, Kam CM, Ricketts KM, Casillas RP: Cutaneous protease activity in the mouse ear vesicant
model. J. Appl. Toxicol. 2000;(suppl 1):S177–S182.
4. CowanFM,BroomfieldCA,SmithWJ.Suppressionofsulfurmustard–increasedIL-8inhumankeratinocyte
cell cultures by serine protease inhibitors: implications for toxicity and medical countermeasures. Cell Biol.
Toxicol. 2002;18:175–180.
5. Holmes WW, Schroth JM, Anderson AR. Evaluation of aprotinin as a treatment for sulfur mustard (SM)–
induced lung injury. FASEB 2006; Abstract #429.6, April 1–5, San Francisco.
6. Anderson AR, Schroth JM, Holmes WW. Evaluation of ilomastat, a matrix metalloprotease inhibitor, as
a treatment for sulfur mustard (SM) inhalation injury. FASEB. 2006; Abstract # 429.7, April 1–5, San
Francisco.
7. Sprecher CA, Kisiel W, Mathewes S, et al. Molecular cloning, expression, and partial characterization of a
second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA.1994;91:3353–3357.
8. Petersen LC, Sprecher CA, Foster DC, et al. Inhibitory properties of a novel human Kunitz-type protease
inhibitor homologous to tissue factor pathway inhibitor. Biochemistry. 1996;35:266–272.
9. Du X, Chand HS, Kisiel W. Human tissue factor pathway inhibitor-2 does not bind or inhibit activated
matrix metalloproteinase-1. Biochim Biophys Acta. 2003;1621:242–245.
10. Herman MP, Sukhova GK, Kisiel W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix
metalloproteinases with implications for atherosclerosis. J Clin Invest. 2001;107:1117–1126.
11. Kong D, Ma D, Bai H, et al. Expression and characterization of the first Kunitz-Domain1 of human tissue
factor pathway inhibitor-2. Biochem Biophys Res Commun. 2004;324:1179–1185.
12. Rao CN, Mohanam S, Puppala A, et al. Regulation of proMMP-1 and pro-MMP-3 activation by tissue
factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Biochem Biophys Res Commun.
1999;255:94–99.
13. Rao CN, Peavey CL, Liu YY, et al. Partial characterization of matrix-associated serine protease inhibitors
from human skin cells. JI n vest Dermatol. 1995;1004:379–383.
14. Rao CN, Gomez DA, Woodley DT, et al. Partial characterization of novel serine protease inhibitors from
human umbilical vein endothelial cells. Arch Biochem Biophys. 1995;319:55–62.
15. Rao CN, Liu YY, Peavey CL, et al. Novel extracellular matrix–associated serine proteinase inhibitors from
human skin fibroblasts. Arch Biochem Biophys. 1995;317:311–314.
16. Rao CN, Reddy P, Liu YY, et al. Extracellular matrix–associated serine protease inhibitors (Mr 33000,
31000, and 27000) are single gene products with differential glycosylation: cDNA cloning of the 330 kDa
inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch Biochem Biophys. 1996;335:45–52.
17. LiuYY,StackSM,LakkaSS,etal.Matrix-localizationoftissuefactorpathwayinhibitor-2matrix-associated
serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and
dermatansulfate:HeparinacceleratestheactivityofTFPI-2/MSPItowardsplasmin.ArchBiochemBiophys.
1999;370;112–118.
18. Kamei S, Petersen LC, Sprecher CA, et al. Inhibitory properties of human recombinant Arg24 Gln type-2
tissue factor pathway inhibitor (R24Q TFPI-2). Thromb Res 1999;94:147–152.
19. RaoCN,CookB,LiuYY,etal.HT-1080fibrposarcomacellmatrixdegradationandinvasionareinhibitedby
tissuefactorpathwayinhibitor-2/matrix-associatedserineproteaseinhibitor.IntJCancer.1998;76:749–756.
20. SchmidtAE,ChandHS,CascioD,etal.CrystalstructureofKunitzdomain1(KD1)oftissuefactorpathway
inhibitor-2 in complex with trypsin. J Biol Chem. 2005;280:27832–27838.
21. Stone MJ, Ruf W, Miles DJ, et al. Recombinant soluble human tissue factor secreted by Saccharomyces
cerevisiae and refolded from Escherichia coli inclusion bodies: glycosylation of mutants, activity and
physical characterization. Biochem J. 1995;310:605–614.
22. ChaD,O’BrienP,O’TooleEA,etal.Enhancedmodulationofkeratinocytemotilitybytransforminggrowth
factor-alpha(TGF-alpha)relativetoepidermalgrowthfactor(EGF).JIn vestDermatol.1996;106:590–597.
23JOURNAL OF BURNS AND WOUNDS VOLUME 7
23. Towbin H, Staehelin T, Godon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocel-
lulose sheets: procedures and some applications. Proc Natl Acad Sci USA. 1979;76:4350–4354.
24. Laemmli U. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature
1970;227:680–682.
25. ChandHS,SchmidtAE,BajajSP,etal.Structure-functionanalysisofthereactivesiteinthefirstKunitz-type
domain of human tissue factor pathway inhibitor-2. J Biol Chem. 2004;279:17500–17507.
24